Extraordinary general meeting of Prolight Diagnostics AB (publ) on 10 June 2025
10 juni, 10:15
The extraordinary general meeting (EGM) of Prolight Diagnostics AB (publ) (the “Company”) took place on 10 June 2025 in Lund. The EGM resolved in accordance with the proposals by the board of directors. The main content of the main resolutions is described below.
Resolution on approval of the board of directors' resolution to issue shares with pre-emption right for existing shareholders.
The EGM resolved, in accordance with the proposal by the board of directors, to approve the board of directors' resolution from 21 May 2025 to issue shares with pre-emption right for the Company's existing shareholders. The resolution means that the Company's share capital is increased by not more than SEK 50,149,248. A maximum of 501,492,480 shares may be issued. Existing shareholders have pre-emption right to subscribe for shares in proportion to the number of shares they already own. For each existing share held on the record date, shareholders will receive one (1) subscription right. Seven (7) subscription rights entitle the right to subscribe for five (5) shares.
The record date for participation in the rights issue is 12 June 2025. Subscription of shares with pre-emption rights shall be made by cash payment during the period from and including 16 June up to and including 30 June 2025. The issue price for each share will be SEK 0.20. The full resolution is set out in the notice.
For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com
About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.
Attachments
Extraordinary general meeting of Prolight Diagnostics AB (publ) on 10 June 2025
Ämnen i artikeln
Extraordinary general meeting of Prolight Diagnostics AB (publ) on 10 June 2025
10 juni, 10:15
The extraordinary general meeting (EGM) of Prolight Diagnostics AB (publ) (the “Company”) took place on 10 June 2025 in Lund. The EGM resolved in accordance with the proposals by the board of directors. The main content of the main resolutions is described below.
Resolution on approval of the board of directors' resolution to issue shares with pre-emption right for existing shareholders.
The EGM resolved, in accordance with the proposal by the board of directors, to approve the board of directors' resolution from 21 May 2025 to issue shares with pre-emption right for the Company's existing shareholders. The resolution means that the Company's share capital is increased by not more than SEK 50,149,248. A maximum of 501,492,480 shares may be issued. Existing shareholders have pre-emption right to subscribe for shares in proportion to the number of shares they already own. For each existing share held on the record date, shareholders will receive one (1) subscription right. Seven (7) subscription rights entitle the right to subscribe for five (5) shares.
The record date for participation in the rights issue is 12 June 2025. Subscription of shares with pre-emption rights shall be made by cash payment during the period from and including 16 June up to and including 30 June 2025. The issue price for each share will be SEK 0.20. The full resolution is set out in the notice.
For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com
About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.
Attachments
Extraordinary general meeting of Prolight Diagnostics AB (publ) on 10 June 2025
Ämnen i artikeln
-992x558.png&w=3840&q=75)
Fortnox-budet
-992x558.png&w=3840&q=75)
Investmentbolagen
-160x160.png&w=3840&q=75)
-160x160.jpg&w=3840&q=75)
Storbritannien
Aktieråd
-992x558.jpg&w=3840&q=75)
Fortnox-budet
Investmentbolagen
Storbritannien
Aktieråd
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
-160x160.jpg&w=3840&q=75)